Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Endo Health Solutions Inc    ENDP

SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Endo Pharmaceuticals Swings To 1Q Loss On Litigation Impacts

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/01/2012 | 02:13pm CET

Endo Pharmaceuticals Holdings Inc.'s (>> Endo Pharmaceuticals Holdings Inc) swung to a first-quarter loss, mostly owing to a $110 million charge related to a 2010 litigation settlement, while the pharmaceutical company reported revenue grew with a boost from a recent acquisition.

Endo has seen its revenue rise in recent quarters, aided by acquisitions that expanded its generic-drug business and core painkiller franchise. But the related charges have hurt its bottom line of late.

First-quarter sales were expected to be affected by a temporary shutdown of a Novartis AG (NVS, Z.NOV) plant in Nebraska to address potential packaging errors. The plant manufactures some Endo products such as its Opana ER painkiller. In the latest period, Opana ER sales were down 4.2%. On Tuesday the company said Opana ER and Voltaren Gel now in steady supply.

Endo reported a loss of $87.3 million, or 75 cents a share, compared with a year-earlier profit of $55.8 million, or 46 cents a share. Excluding impacts from a 2010 litigation settlement with Impax Laboratories Inc. (IPXL), adjusted earnings were down at 87 cents from $1. The company in February expected earnings below 90 cents amid a temporary shutdown at the Novartis plant.

Revenue increased 23% to $691 million, with a boost from its American Medical Systems acquisition. Analysts polled by Thomson Reuters most recently projected $702 million.

Gross margin fell to 47.2% from 58.7%.

Sales of Lidoderm, which makes up the biggest chunk of Endo's top line, were up 11%.

Overall branded drug sales were down 3% while generics sales increased 8%.

Shares of Endo, which reaffirmed its 2012 guidance, closed Monday at $35.14 and were inactive premarket. The stock is down roughly 10% in the past year.

-By Tess Stynes, Dow Jones Newswires; 212-416-2481; Tess.Stynes@dowjones.com

Stocks mentioned in the article : Endo Pharmaceuticals Holdings Inc
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ENDO HEALTH SOLUTIONS INC
01/12 ENDO INTERNATIONAL PLC : Biotech and Healthcare Stocks Hit Hard by President Tru..
01/04 ENDO INTERNATIONAL PLC : Bronstein, Gewirtz & Grossman, LLC Reminds Investors of..
2016 U.S. stock market performance in 2016
2016 ENDO INTERNATIONAL PLC : Bronstein, Gewirtz & Grossman, LLC Reminds Investors of..
2016 ENDO INTERNATIONAL PLC : Lundin Law PC Announces Securities Class Action Lawsuit..
2016 ENDO INTERNATIONAL PLC : SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC ..
2016 ENDO INTERNATIONAL PLC : Levi & Korsinsky, LLP Notifies Shareholders of Endo Int..
2016 ENDO INTERNATIONAL PLC : SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC ..
2016DJENDO INTERNATIONAL : Sells Back Rights for Opioid Painkiller
2016 ENDO INTERNATIONAL PLC : Bronstein, Gewirtz & Grossman, LLC Reminds Investors of..
More news
Sector news : Generic Pharmaceuticals
01/13DJNOVARTIS : Supreme Court to Weigh How Soon Firms Can Sell Copycat Biotech Drugs
01/13DJLONDON MARKETS : FTSE 100 Continues Record Run, Rising For 14th Day In A Row
01/13 FTSE hits record highs, extends historic winning streak
01/12DJCigna Drops Coverage of Mylan's EpiPen for Cheaper Generic -- Update
01/12 Investors in big pharma, biotech look to ride out Trump storm
More sector news : Generic Pharmaceuticals
Advertisement
Financials ($)
Sales 2016 3 930 M
EBIT 2016 1 484 M
Net income 2016 -332 M
Debt 2016 7 987 M
Yield 2016 -
P/E ratio 2016 32,37
P/E ratio 2017 7,56
EV / Sales 2016 2,78x
EV / Sales 2017 2,59x
Capitalization 2 940 M
More Financials
Technical analysis trends ENDO HEALTH SOLUT...
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 23,2 $
Spread / Average Target 76%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Paul V. Campanelli President, Chief Executive Officer & Director
Roger H. Kimmel Chairman
Terrance J. Coughlin Chief Operating Officer & Executive Vice President
Blaise Coleman Chief Financial Officer & Executive Vice President
Robert J. Cobuzzi SVP-Operations, Research & Development Strategy
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ENDO HEALTH SOLUTIONS ..2 940
OTSUKA HOLDINGS CO LTD10.94%27 521
SUN PHARMACEUTICAL IND..3.68%22 985
ONO PHARMACEUTICAL CO...-2.03%12 896
ASPEN PHARMACARE HOLDI..1.92%9 832
SHANGHAI FOSUN PHARMAC..2.68%8 169
More Results